iSpecimen Inc. (NASDAQ:ISPC) Short Interest Down 99.1% in April

iSpecimen Inc. (NASDAQ:ISPC) was the recipient of a significant decline in short interest in the month of April. As of April 30th, there was short interest totaling 51,489 shares, a decline of 99.1% from the April 15th total of 5,529,018 shares. Currently, 7.9% of the company’s shares are sold short. Based on an average daily volume of 1,959,292 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

ISPC has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of iSpecimen in a research note on Tuesday, April 21st. Wall Street Zen raised shares of iSpecimen to a “sell” rating in a research note on Saturday, May 2nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Institutional Trading of iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Virtu Financial LLC acquired a new position in iSpecimen Inc. (NASDAQ:ISPC) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned 0.65% of iSpecimen at the end of the most recent reporting period. 13.62% of the stock is owned by institutional investors.

iSpecimen Stock Down 1.4%

NASDAQ:ISPC traded down $0.07 during mid-day trading on Monday, reaching $5.05. The company’s stock had a trading volume of 359,243 shares, compared to its average volume of 1,770,498. iSpecimen has a 1 year low of $4.00 and a 1 year high of $127.20. The stock has a fifty day moving average of $6.75 and a 200-day moving average of $13.78. The firm has a market capitalization of $3.74 million, a PE ratio of -0.05 and a beta of 1.75.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.